Investigational drug · Phase 2
AZD8630
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Asthma.
Phase 2Last checked: Nov 19, 2026Latest source record: Mar 2, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
5
Any phase or sponsor naming "AZD8630"
First trial start
2024
Aug 30, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "AZD8630", any sponsor or status.
Conditions studied
As listed on its trial records.
- Asthma
Approved drugs for the same conditions: Asthma · Respiratory
Largest trials
Live from ClinicalTrials.gov: studies naming "AZD8630" as an intervention, largest first.
- A Dose Range-Finding Study to Assess the Efficacy and Safety of Multiple Dose Levels of AZD8630 in Adults With Uncontrolled Asthma at Risk of ExacerbationsPivotal-lookingCompleted
AstraZenecaAstraZeneca (AZN)
NCT06529419 · 537 participants · Start Aug 30, 2024 · Primary completion Feb 4, 2026
Drug: AZD8630; Placebo · For: Asthma
Sites: Mesa, Arizona; Huntington Beach, California; La Mesa, California · 196 sites in all
- A Study to Investigate the Safety, Tolerability and Effects of AZD8630 in Healthy Subjects and Subjects With Asthma on Inhaled Corticosteroids and Long-acting Beta-agonistsPivotal-lookingCompleted
AstraZenecaAstraZeneca (AZN)
NCT05110976 · 170 participants · Start Dec 16, 2021 · Primary completion Aug 2, 2023
Drug: AZD8630; Placebo · For: Asthma
Sites: Tempe, Arizona; Bakersfield, California; Glendale, California · 29 sites in all
AstraZenecaAstraZeneca (AZN)
NCT06531811 · 32 participants · Start Aug 6, 2024 · Primary completion Oct 3, 2024
Drug: AZD8630 (test formulation) via test inhaler; AZD8630 (reference formulation) via Monodose inhaler · For: Healthy Participants
Sites: Baltimore, Maryland
AstraZenecaAstraZeneca (AZN)
NCT06795906 · 24 participants · Start Jan 28, 2025 · Primary completion Jun 27, 2025
Drug: AZD8630 · For: Asthma
Sites: Ahrensburg, Germany; Berlin, Germany; Mainz, Germany
AstraZenecaAstraZeneca (AZN)
NCT07065331 · 10 participants · Start Jun 11, 2025 · Primary completion Sep 19, 2025
Drug: AZD8630 · For: Asthma
Sites: Bakersfield, California; Miami Lakes, Florida; Lafayette, Louisiana · 9 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- AZD8630/AMG 104, an inhaled anti-thymic stromal lymphopoietin antibody fragment, for moderate-to-severe asthma: Phase 1 randomized controlled trial.
Doffman SR, Dosanjh DPS, Sadiq MW, et al. · J Allergy Clin Immunol 2026
Also in development for Asthma
- CM512Phase 39 trials
Keymed Biosciences Co.Ltd · Chronic Rhinosinusitis With Nasal Polyposis, Chronic Spontaneous Urticaria (CSU), Asthma
- LunsekimigSAR443765Phase 39 trials
Sanofi · Asthma, Chronic Obstructive Pulmonary Disease, Chronic Rhinosinusitis With Nasal Polyps
- GSK5784283Phase 38 trials
GSK · Pulmonary Disease, Chronic Obstructive, Asthma, Nasal Polyps
- PF-07275315tilrekimigPhase 38 trials
Pfizer · Atopic Dermatitis, Asthma, Moderate to Severe Chronic Obstructive Pulmonary Disease
- MG-K10Humanized Monoclonal AntibodyPhase 36 trials
Shanghai Mabgeek Biotech.Co.Ltd · Dermatitis, Atopic, Chronic Urticaria, Idiopathic, Atopic Dermatitis
- SHR-1905Phase 36 trials
Guangdong Hengrui Pharmaceutical Co., Ltd · Asthma, Chronic Rhinosinusitis With Nasal Polyps, Moderate-to-severe Atopic Dermatitis
- TozorakimabMEDI3506Phase 36 trials
AstraZeneca · Chronic Obstructive Pulmonary Disease (COPD), Asthma, Viral Lung Infection and Acute Respiratory Failure
- TQC2731Phase 35 trials
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. · Asthma, Chronic Obstructive Pulmonary Disease, Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from AstraZeneca.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.